
Regentis Biomaterials makes GelrinC, a cell-free off-the-shelf hydrogel implant that surgeons cure into the knee to treat articular cartilage injuries.
GelrinC gives knee surgeons a single, approximately 10-minute procedure, while autologous cell therapies such as Vericel's MACI require two surgeries, with cartilage first harvested from the patient for cell expansion and then implanted as cultured cells, at a cost of around $40,000 in the US. Clinical studies report a short recovery period after the GelrinC procedure.
Regentis Biomaterials holds 34 granted patents and four pending patent applications covering compositions, delivery devices and surgical features. GelrinC is approved as a device with a CE mark in Europe.
The global knee cartilage repair market's projected expansion lifts GelrinC's revenue opportunity, and cell-based therapies such as matrix-associated chondrocyte implantation (MACI) are established alternatives in that market. The market was valued at USD 1.28 billion in 2024 and is projected to grow from USD 1.37 billion in 2025 to USD 2.33 billion by 2033 at a 6.84% CAGR in the 2026-2033 forecast period. Established cartilage repair techniques also include microfracture and cell-based therapies such as autologous chondrocyte implantation (ACI).
Cell-based cartilage resurfacing stands as the fastest-growing segment of the knee cartilage repair market, propelled by regenerative medicine and tissue engineering advances, while the US orthopedic market for knee cartilage injuries is estimated at $4 billion annually across 750,000 arthroscopic knee operations.
A delayed PMA risks keeping GelrinC out of the US market because approval depends on an 80-patient pivotal trial requiring two years of follow-up data. Regentis Biomaterials targets a PMA submission by the end of 2027, and 47 patients have been recruited and enrolled in the study to date.
The pivotal trial is an open-label, single-arm study using only a treatment arm and Regentis Biomaterials' own historical microfracture control. The company priced a private placement at $3.50 per ordinary share plus an accompanying ordinary warrant, expecting approximately $6.5 million in aggregate gross proceeds.
Regentis Biomaterials' lead product GelrinC is a cell-free, off-the-shelf hydrogel that surgeons transform into a knee implant for painful articular knee cartilage injuries by crosslinking polyethylene glycol di-acrylate (PEG-DA) and denatured fibrinogen with UVA light directly in the lesion.
GelrinC is implanted in a single step following standard microfracture treatment, lengthening the procedure by approximately 10 minutes, and gradually degrades within 6-12 months as regenerated cartilage replaces it.